Christof Vulsteke onbezoldigd gastprofessor

Publicaties Christof Vulsteke

Perioperative enfortumab vedotin and pembrolizumab in bladder cancer

Bron
The New England journal of medicine - ISSN 0028-4793-394:13 (2026) p. 1257-1269
Auteur(s)
    Christof Vulsteke, Nabil Adra, Pongwut Danchaivijitr, Maksym Sabadash, Alejo Rodriguez-Vida, Zhentao Zhang, Vagif Atduev, Y. Emre Goger, Steffen Rausch, Seok-Ho Kang, Yohann Loriot, Jens Bedke, Matthew D. Galsky, Peter H. O'donnell, Gunhild Von Amsberg, Nimira Alimohamed, Grzegorz Sulimka, Shilpa Gupta, Viktor Paramonov, Keita Nakane, Michael Mihm, Changting Meng, Caizhi David Huang, Chethan Ramamurthy, Blanca Homet Moreno, Anders Ullen

First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer : 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial

Bron
International journal of gynecological cancer - ISSN 1048-891X-36:1 (2026) p. 1-7
Auteur(s)
    Christian Marth, Richard G. Moore, Mariusz Bidzi, Vanda Salutari, Ozden Altunda, Maria Jesus Rubio, Tally Levy, Alison Stillie, Christof Vulsteke, Ralf Witteler, Kazuya Ariyoshi, Xiaohua Wu, Sophia Frentzas, Andre Mattar, Brian M. Slomovitz, Stephanie Lheureux, Xiaojun Chen, Kosei Hasegawa, Manuel Magallanes, Chel Hun Choi, Mariia Shalkova, Diego Lucas Kaen, Karen Cadoo, Lili Yao, Jodi Mckenzie, Chinyere E. Okpara, Robin Meng, Robert Orlowski, Lucy Gilbert, Vicky Makker

A plain language summary of the TROPiCS-04 study : sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tract

Bron
Future oncology - ISSN 1479-6694-21:28 (2025) p. 3593-3610
Auteur(s)
    Thomas Powles, Scott T. Tagawa, Christof Vulsteke, Marine Gross-Goupil, Se Hoon Park, Andrea Necchi, Maria De Santis, Ignacio Duran, Rafael Morales-Barrera, Jun Guo, Cora N. Sternberg, Joaquim Bellmunt, Peter J. Goebell, Maria Kovalenko, Freda Boateng, Mitch Sierecki, Lu Wang, Camelia S. Sima, Jana Waldes, Rick Bangs, Yohann Loriot, Petros Grivas

Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma : 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial

Bron
Annals of oncology - ISSN 0923-7534-36:10 (2025) p. 1-8
Auteur(s)
    T.B. Powles, M.S. Van der Heijden, Y. Loriot, J. Bedke, B.P. Valderrama, G. Iyer, E. Kikuchi, J. Hoffman-Censits, Christof Vulsteke, A. Drakaki, S. Rausch, W. Arafat, S.H. Park, U. Swami, J.-r. Li, I. Duran, S. Gorla, B. Homet Moreno, X. Yu, Y.-t. Lu, S. Gupta

Exploratory subgroup analyses of EV-302 : a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma

Bron
ESMO Open - ISSN 2059-7029-10:8 (2025) p. 1-9
Auteur(s)
    M.S. van der Heijden, T. Powles, S. Gupta, Y. Loriot, M.D. Galsky, B.P. Valderrama, S.S. Sridhar, E.Y. Yu, G. Iyer, E. Kikuchi, D. Castellano, J. Hoffman-Censits, A. Drakaki, N. Mar, J.P. Maroto Rey, Christof Vulsteke, W. Arafat, I. Duran, N.A. Dawson, U. Swami, S. Gorla, B.H. Moreno, X. Yu, Y.-T. Lu, J. Bedke